Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
Posted in -
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Posted in -
Sharing Drug Rebates With Medicare Part D Patients: Why And How
The percentage of total Medicare Part D drug spending offset by rebates on branded drugs increased from 11% in 2010 to 25% in 2018.
-
Are U.S. Health Care Prices Too High, Too Low, or Some Mix of the Two?
Part 1 of a panel series on health care price regulation honoring Uwe E. Reinhardt (1937-2017)
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
Categorized in -
Ten Actions For Better Post-Pandemic Healthcare In The United States
What changes should be made now to the U.S. healthcare system to make it better when things return to a new normal, and, in the event of future pandemics.
Categorized in -
Uptake of Infliximab Biosimilars Among the Medicare Population
Two years after launch, biosimilars for rheumatoid arthritis and other lifelong conditions captured little market share.
Categorized in -
California Leads in Public Investment in Biomedical Innovation and It Is Beginning to Show Returns
Schaeffer Center research indicates public investment into biomedical innovation yields substantial economic and social return in California.
Categorized in -
The Economic Case for Public Investment in Stem Cell Research
Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.
Categorized in -
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the U.S.
In a study published in Pharmacoeconomics, we find multiple blockbuster drugs have received exclusivity of more than 10 years through the Orphan Drug Act, thereby delaying access to generic/biosimilar equivalents.
Categorized in